Robert J. Schott

SVP, Head of Development, SANGAMO THERAPEUTICS, INC.

Companies

SANGAMO THERAPEUTICS, INCSVP, Head of Development Feb 10, 2021 to Mar 1, 2022¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

SANGAMO THERAPEUTICS, INC SGMOQ75,537 shares²$10.7K at $0.14Feb 25, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

Feb 25, 2022Granted 41,000 shares of SANGAMO THERAPEUTICS, INC²
Feb 12, 2022Shares withheld for tax 5,463 shares at $5.76 of SANGAMO THERAPEUTICS, INC³

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSANGAMO THERAPEUTICS, INC, SVP, Head of Development
2
SEC EDGARSANGAMO THERAPEUTICS, INC shares after the filing of Feb 25, 2022
3
SEC EDGARForm 4 filed Feb 24, 2022